UbiQ was founded in 2010 as a spin-out of the Netherlands Cancer Institute (Amsterdam, The Netherlands).
At UbiQ we develop and commercialize ubiquitin-based research tools, enabling drug discovery in the emerging ubiquitin field. Our products are targeted at pharmaceutical companies and academic research labs. Moreover, we develop assays for high-throughput screening, both for internal drug discovery projects and those partnered with pharmaceutical companies.
Next to the reagent business, we have been focussing increasingly on our own drug discovery programs, based on novel technologies that we have recently developed. For example, we are rationally developing mechanism-based covalent inhibitors of the enzymes involved in protein SUMOylation. Many Myc-driven tumors appear to critically depend on hyper-SUMOylation. SUMOylation inhibitors can revert the hyper-SUMOylation state and thus specifically kill Myc-driven tumors.
For more info on us or our products please visit: www.ubiqbio.com and www.sumiqtx.com
Company Details
- Employees
- 5
- Founded
- -
- Address
- Science Park 408, Amsterdam,noord-Holland 1098 Xh,netherlands
- Phone
- +31 (0)20 303 1970
- Industry
- Biotechnology
- Website
- ubiqbio.com
- Keywords
- ubiquitin research tools, drug discovery in the ubiquitin field, synthetic lethality, ubiquitin-like probes, custom-made.
- HQ
- Amsterdam, Noord-Holland
Ubiq Questions
Ubiq's helpline number is +31 (0)20 303 1970
Ubiq's website is ubiqbio.com
Ubiq's LinkedIn profile is https://nl.linkedin.com/company/ubiq
Ubiq has
5 employees.
View email and phone details for 5
employees at Ubiq.
Ubiq's industry is
Biotechnology
Ubiq's top competitors are
Open Kitchen Labs,
Octorelease,
Gyes Bv,
Spark904,
Belbird Technologies,
Bbb Therapeutics,
Biolytics Ai,
Crcbioscreen B.v.,
Cosimi Bio,
Photanol.
Ubiq's categories are Biotechnology
Ubiq's founding year is 2010
